Antidepressant use during early pregnancy and the risk of congenital anomalies

Pharmacotherapy

Volumn 33, Issue 7, 2013, Pages 693-700

  Vasilakis Scaramozza, Catherine ^a   Aschengrau, Ann ^a   Cabral, Howard ^a   Jick, Susan S ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Congenital anomalies; Prevalence rates; Relative risk

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR MALFORMATION; CENTRAL NERVOUS SYSTEM MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; EAR MALFORMATION; EYE MALFORMATION; FACE MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; GENITAL MALFORMATION; HUMAN; MAJOR CLINICAL STUDY; NECK MALFORMATION; OUTCOME ASSESSMENT; PREVALENCE; PROGENY; RISK ASSESSMENT; RISK FACTOR; URINARY TRACT MALFORMATION;

ANTIDEPRESSANTS; CONGENITAL ANOMALIES; PREVALENCE RATES; RELATIVE RISK;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COHORT STUDIES; CONGENITAL ABNORMALITIES; DATABASES, FACTUAL; DEPRESSION; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREVALENCE; RISK; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84885413282     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1211     Document Type: Article

References (40)

1. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
2. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999;282:1264-9.
3. Emslie G, Judge R. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/ adolescents and in the elderly. Acta Psychiatr Scand Suppl 2000;403:26-34.
4. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8.
5. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
6. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998;279:609-10.
7. Gentile S. Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions. CNS Spectr 2008;13:960-6.
8. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96.
9. Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701-4.
10. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-92.
11. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27.
12. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:474-84.
13. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-8.
14. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83.
15. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
16. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-7.
17. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011;91:142-52.
18. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Nørgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36.
19. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111-20.
20. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
21. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-61.
22. Jick H, Jick S, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8.
23. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992;1:347-9.
24. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25.
25. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9.
26. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997;17:561-4.
27. Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999;19:221-2.
28. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-8.
29. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14.
30. Iqbal MM, Sohhan T, Mahmud SZ. The effects of lithium, valproic acid, and carbamazepine during pregnancy and lactation. J Toxicol Clin Toxicol 2001;39:381-92.
31. Kroes HY, Reefhuis J, Cornel MC. Is there an association between maternal carbamazepine use during pregnancy and eye malformations in the child? Epilepsia 2002;43:929-31.
32. Misirlioglu ED, Aliefendioglu D, Dogru MT, Sanli C, Oktay A. Transposition of the great arteries in a newborn whose mother was treated with carbamazepine during pregnancy. Anadolu Kardiyol Derg 2007;7:344-5.
33. James L, Barnes TR, Lelliott P, Taylor D, Paton C. Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists. J Psychopharmacol 2007;21:815-9.
34. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271: 146-50.
35. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-3.
36. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280-4.
37. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30.
38. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003;48:106-10.
39. Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54:242-6.
40. Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2003;67:193-201.